this news is worth reading...

Welcome [Sign In] To track stocks & more, Register
Financial News
Enter symbol(s) BasicPerformanceReal-time MktDetailedChartResearchOptionsOrder Book Symbol Lookup

Press Release Source: Sinovac Biotech Ltd.

Sinovac Biotech Ltd. Releases Further Results From SARS Vaccine Phase I Human Clinical Trial
Monday December 13, 9:05 am ET

BEIJING--(BUSINESS WIRE)--Dec. 13, 2004--Sinovac Biotech Ltd. ("Sinovac") ("the Company") (AMEX:SVA - News) announces that its SARS vaccine has induced SARS-neutralizing antibodies in tests of the human volunteers' blood serum. After the preliminary 56-day observation period, 11 out of 12 (91.6%) of the volunteers who received high-dosage vaccine and 12 out of 12 (100%) of the volunteers who received low-dosage vaccine showed blood serum conversion. Blood serum conversion is the ability of the induced antibodies to neutralize the SARS virus. These preliminary results show that the SARS vaccine Phase I clinical trial has already attained a positive outcome.